Medical Developments International shares on watch following Penthrox update

The Medical Developments International Ltd (ASX:MVP) share price will be on watch today after the release of a Penthrox update…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Medical Developments International Ltd (ASX: MVP) share price will be on watch this morning follow a positive announcement relating to its Penthrox product.

a woman

What is Penthrox?

Penthrox, or the green whistle, is a fast onset, non-opioid analgesic. It is indicated for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures.

It has been used safely and effectively for over 40 years in Australia with more than 5 million units sold.

In recent times the company has been looking at expanding its use, hence today's announcement.

What did Medical Developments International announce?

This morning the healthcare company announced that data across 11 abstracts of studies conducted throughout Europe have demonstrated multiple positive results of Penthrox.

This includes Penthrox demonstrating superiority over intravenous (IV) morphine, paracetamol, ketoprofen, and NSAIDS within a trauma setting.

It also found that Penthrox added to the standard of care (SoC) demonstrates superiority over SoC plus a placebo within a trauma setting.

The product was also successful in dislocation injuries. Its use resulted in reduced time spent in the Emergency Departments, which improves the patient experience and reduces crowding.

The release explains that other studies confirmed previously published data. This includes Penthrox being an efficacious, well tolerated/safe and rapidly acting analgesic in trauma settings.

Another positive was that the studies commonly reported that Penthrox exceeded patient/clinician expectations and/or resulted in a high degree of treatment satisfaction from patients and health care professionals.

The company's CEO, John Sharman, was delighted with the study results.

He said: "We are delighted with the results of these recent European clinical trials demonstrating superiority of Penthrox over Standard of Care treatments (intravenous (IV) morphine, IV paracetamol, ketoprofen or NSAIDS) within the acute trauma setting. This reinforces the global potential for Penthrox as a simple, fast and effective non-opioid pain medication."

James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Medical Developments International Limited. The Motley Fool Australia has recommended Medical Developments International Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

A man with a wide, eager smile on his face holds up three fingers.
Broker Notes

Brokers name 3 ASX shares to buy right now

Let's find out which shares top brokers are feeling bullish about this week.

Read more »

A person trying to step over a crack.
Record Highs

BHP shares hit a record high this week. Is the rally about to crack?

BHP shares are cooling after a huge run this year.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Share Gainers

Why Chalice Mining, CSL, Megaport, and Pro Medicus shares are racing higher

These shares are having a strong finish to the week. But why?

Read more »

A woman wearing green flexes her bicep.
Broker Notes

7 ASX 200 shares with strengthened buy ratings this week

Brokers have indicated continuing confidence in BHP, AMP, IAG, Megaport, and others. 

Read more »

Businessman studying a high technology holographic stock market chart.
Broker Notes

Canaccord Genuity has just added these two ASX 200 shares to its best ideas list

These two very different shares are tipped to outperform.

Read more »

A woman looks unimpressed on a blue background.
Broker Notes

6 ASX 200 shares downgraded by analysts this week

Brokers reduced their ratings on CSL, Telstra, Droneshield, and other ASX 200 stocks this week. 

Read more »

Two people shake hands making a deal about green energy.
Mergers & Acquisitions

This beaten-down ASX stock just jumped on a $55 billion deal

Perpetual shares are higher after a new deal caught attention.

Read more »

A woman in a red dress holding up a red graph.
Broker Notes

Brokers name 3 ASX shares poised for 52% to 78% gains

These three shares are undervalued, according to the experts.

Read more »